<div id="readability-page-1"><p>Mizuho Securities analyst Uy Ear upgraded Relmada Therapeutics to a Buy today and set a price target of $10.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Ear covers the Healthcare sector, focusing on stocks such as Tectonic Therapeutic, Sarepta Therapeutics, and Alkermes. According to TipRanks, Ear has an average return of <span>-1.3%</span> and a 37.82% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Hold analyst consensus rating for Relmada Therapeutics.</p></div>

RLMD

<p>Mizuho Securities analyst Uy Ear upgraded Relmada Therapeutics (RLMD) to a Buy with a price target of $10.00. Despite a general Hold consensus, Ear focuses on the Healthcare sector and has an average return of -1.3% with a 37.82% success rate on stock recommendations.</p>

Mizuho Securities upgrades Relmada Therapeutics (RLMD) to a Buy